LOGIN  |  REGISTER
Amneal Pharmaceuticals

VitalHub Announces Partnership with HammondCare for a Low-Carbon Dementia Care Initiative

April 27, 2023 | Last Trade: C$6.03 0.13 -2.11

TORONTO, April 27, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce a partnership between the Company’s MyPathway platform and HammondCare, aimed at enhancing patient care in England while supporting the National Health Service (NHS) to contribute to its green footprint in their journey to reach Net Zero by 2040.

MyPathway, is an app-based patient portal solution, which connects patients to care services in areas including muscular-skeletal, chronic pain, motor neurone disease, and eating disorders. It can be accessed through a web browser on a computer, phone, tablet, or via the custom-built MyPathway App. MyPathway is a leading digital health portal platform that will allow VitalHub, alongside Intouch with Health’s Flow Manager, to truly offer end-to-end patient flow and is one of the first solutions of its kind in the UK healthcare marketplace.

"HammondCare's selection of MyPathway for their patient portal is a significant milestone, marking the first major commercial development into a new care area since VitalHub's acquisition of ADI Health (MyPathway)," stated Dan Matlow, CEO of VitalHub. "We are excited to showcase the capabilities of MyPathway technology in the patient portal space. The unique value proposition MyPathway delivers was a key factor in HammondCare's decision, and we anticipate continued end market traction of this platform."

The new partnership will develop and deploy the Virtual Dementia Behaviour Support Clinic - a specialist, virtual clinic, accessible anywhere and anytime for family, unpaid and paid carers of people experiencing noticeable symptoms associated with dementia.

“By reducing the need for in-person consultations and emergency visits and support, the Virtual Dementia Behaviour Support Clinic helps to minimise travel, staff and resource use and reduce carbon emissions by providing the right advice to carers and targeting in-person assistance to when it's needed,” said Dr Julie Christie, Programme Manager at HammondCare. “This makes it an ideal solution for Integrated Care Boards and Primary Care Networks that want to prioritise both patient care and environmental sustainability targets. The number of patients with dementia in the UK continues to grow rapidly and is expected to increase to over one million people by the year 20251, which will only further intensify the demand on the existing dementia care pathways. The Virtual Dementia Behaviour Support Clinic will help relieve some of this pressure, and we are proud to be part of this project.”

1 https://www.alzheimers.org.uk/blog/how-many-people-have-dementia-uk 

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.

VitalHub provides technology to Health and Human Services providers including Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination & Optimization, and Patient Flow & Operational Visibility solutions.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 400 clients across Canada, USA, UK, Australia, the Middle East, and Europe.

VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 300 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol “VHIBF”.

https://www.VitalHub.com/

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION:

VitalHub Corp.
Dan Matlow
Chief Executive Officer
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB